Khadeen Patrick Kadirire, NP
Family · Wichita Falls, TXNPI 1245582733
Payments from drug & device makers
Across 421 payments — averaging $45.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$13K
- AbbVie$954
- Amgen$953
- Johnson & Johnson$547
- E.r. Squibb & Sons, L.L.C.$502
- GSK$446
- plus $3K from 23 others
What the payments were for
- Consulting fees$10,63256%
- Travel & lodging$1,2707%
- Food & beverage$6,63135%
- Education$4322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 61 | $12,893 |
| AbbVie | 68 | $954 |
| Amgen(2 entities) | 64 | $953 |
| Johnson & Johnson(2 entities) | 29 | $547 |
| E.r. Squibb & Sons, L.L.C. | 31 | $502 |
| GSK | 26 | $446 |
| AstraZeneca | 18 | $420 |
| Lilly USA, LLC | 18 | $353 |
| Sanofi | 17 | $347 |
| Genentech USA, Inc. | 24 | $339 |
| Pfizer | 19 | $246 |
| Novartis | 13 | $226 |
| Sun Pharmaceutical Industries Inc. | 7 | $215 |
| Boehringer Ingelheim | 4 | $74 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Radius Health, Inc. | 4 | $65 |
| ANI Pharmaceuticals, Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Incyte Corporation | 2 | $31 |
| Mylan Institutional Inc. | 1 | $30 |
| LEO Pharma Inc. | 1 | $25 |
| Organon | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,966 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $36,351 |
| Fluocinonide | 106 | $4,851 |
| Desonide | 64 | $2,960 |
| Ketoconazole | 189 | $2,386 |
| Triamcinolone Acetonide | 115 | $1,971 |
| Clobetasol Propionate | 41 | $1,844 |
| Mometasone Furoate | 57 | $1,269 |
| Doxycycline Hyclate | 79 | $1,181 |
| Clindamycin Phosphate | 31 | $1,104 |
| Azelaic Acid | 15 | $1,084 |
| Imiquimod | 24 | $657 |
| ValacyclovirValacyclovir Hcl | 26 | $578 |
| Hydroxyzine Hcl | 40 | $412 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $325 |
| Fluconazole | 22 | $266 |
Paid to pharmacies, not to this prescriber.
Other family in Wichita Falls
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.